Clinical Trial Update: A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) [Phase 3]

View source ↗

Summary

This ClinicalTrials.gov entry describes a Phase 3 study evaluating the long-term efficacy and safety of KarXT plus KarX-EC for agitation in Alzheimer's disease,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• KarX-EC
• KarXT (xanomeline-trospium)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Alzheimer Disease, Agitation | Phase 3 | Status: RECRUITING